Plain-English translation of NCT07412613 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called AK104 (also called Cadonilimab) for patients with early-stage colon cancer that has specific genetic changes. The trial will compare the medication—given both before and after surgery—to the standard chemotherapy that doctors typically use after surgery. The goal is to see if this new approach helps prevent cancer from coming back.
Standard chemotherapy after colon cancer surgery works, but it doesn't work for everyone and can have significant side effects. This medication belongs to a newer class of cancer drugs that work differently, and researchers want to find out whether it might offer better outcomes with fewer side effects for patients whose cancers have these particular genetic markers.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would receive the medication before surgery, then have your cancer surgery, and then continue receiving the medication after surgery. You would be randomly assigned to either receive AK104 or standard chemotherapy after surgery. Throughout the treatment, you'll have regular clinic visits for blood tests, scans, and check-ups to monitor how well the treatment is working and manage any side effects. The study involves about 386 patients across multiple hospitals.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China